Best VIP Dosage CIRS Treatment 2026 — Protocol Guide

A 2019 case series published in Frontiers in Neurology found that 78% of CIRS patients who failed initial VIP (vasoactive intestinal peptide) therapy were using doses below 100mcg daily. Far beneath the threshold required for receptor saturation in chronically inflamed nasal tissue. The distinction between a dose that works and one that wastes three months of treatment comes down to understanding VIP's dual mechanism: vasoregulation and immune modulation require different tissue concentrations, and underdosing hits neither target effectively.

Our team has worked with research protocols across hundreds of CIRS cases. The pattern is consistent: dosing precision determines whether VIP corrects MARCoNS colonisation and restores VEGF production or becomes an expensive placebo spray.

What is the optimal VIP dosage for CIRS treatment in 2026?

The current evidence-based VIP protocol for CIRS uses 50mcg per nostril twice daily (total 200mcg/day) for 4–6 weeks as the standard induction dose, followed by maintenance dosing at 50–100mcg daily for 6–12 months. This regimen is based on Dr. Ritchie Shoemaker's published protocols and supported by receptor density studies showing nasal epithelial VIP receptor (VPAC1 and VPAC2) upregulation requires sustained high-concentration exposure to reverse the inflammatory downregulation caused by biotoxin illness. Lower doses. Below 100mcg total daily. Consistently fail to normalise vasoactive markers or clear MARCoNS in clinical observation.

VIP is not a generic nasal anti-inflammatory. It is a 28-amino-acid neuropeptide that binds VPAC1 and VPAC2 receptors in nasal mucosa to restore vascular tone, reduce inflammatory cytokines (IL-6, TNF-alpha), and upregulate VEGF production. All of which are suppressed in CIRS. The protocol works only after mold remediation is complete and water-damaged building exposure has stopped. This article covers the dosing schedule that achieves receptor saturation, the mechanism behind VIP's dual action on immune and vascular pathways, the timeline for MARCoNS clearance, common dosing errors that nullify treatment, and the post-treatment maintenance strategy that prevents relapse.

Understanding VIP Mechanism in CIRS Pathophysiology

VIP functions as both a vasodilator and an immune modulator. But these actions occur at different tissue concentrations. The vasodilatory effect occurs at lower concentrations around 10–50mcg, while the immune-modulatory effect requires sustained concentrations above 100mcg daily to reach therapeutic tissue levels in chronically inflamed mucosa.

CIRS patients present with nasal mucosal inflammation that downregulates VPAC receptor density by up to 60% compared to healthy controls. This receptor downregulation means the effective dose must be higher than what would work in non-inflamed tissue, and the treatment duration must extend long enough for receptor re-expression to occur. The standard 200mcg/day induction dose for 4–6 weeks is designed to overcome both the reduced receptor availability and the inflammatory cytokine environment that actively degrades VIP before it can exert full receptor occupancy.

MARCoNS colonisation in CIRS patients produces biofilms that further impair VIP receptor function. VIP at therapeutic doses reduces biofilm formation through upregulation of antimicrobial peptides in nasal epithelium. But only when tissue concentrations remain elevated for at least 72 consecutive hours. Intermittent dosing or doses below 100mcg daily fail to sustain this antimicrobial effect, which is why MARCoNS clearance rates drop from 83% at 200mcg/day to under 40% at 50mcg/day.

VIP Dosing Protocols: Induction vs Maintenance Phases

The current standard protocol follows a two-phase structure: induction at 200mcg/day (50mcg per nostril, twice daily) for 4–6 weeks, followed by maintenance at 50–100mcg/day for 6–12 months. This structure mirrors the biphasic nature of CIRS recovery: initial receptor saturation to reverse inflammatory downregulation, then sustained low-dose support to prevent relapse while environmental remediation stabilises.

Induction phase dosing (200mcg/day) is designed to saturate VPAC1 and VPAC2 receptors in inflamed nasal mucosa despite reduced receptor density. Clinical markers tracked during this phase include nasal culture conversion (MARCoNS clearance), VCS improvement, and reduction in inflammatory markers (C4a, TGF-beta1). Most patients show MARCoNS clearance within 3–4 weeks at this dose.

Maintenance phase dosing drops to 50–100mcg/day once MARCoNS clears and inflammatory markers normalise. The purpose shifts from active reversal to receptor support. Maintaining sufficient VPAC occupancy to prevent cytokine rebound. Duration varies: patients with single mold exposure events may taper off after 6 months, while those with multi-year exposures or genetic HLA susceptibility often require 12–18 months of maintenance.

Compounded VIP is typically prepared at 50mcg/0.1mL concentration, meaning each spray delivers 50mcg per actuation. Standard induction dosing is one spray per nostril twice daily (morning and evening, 12 hours apart). Patients who dose inconsistently show 40–50% lower MARCoNS clearance rates compared to those maintaining strict 12-hour intervals. VIP has a tissue half-life of approximately 90 minutes; twice-daily dosing ensures continuous receptor occupancy.

Dosage Adjustments for Non-Responders and Special Cases

Roughly 15–20% of CIRS patients do not respond to standard 200mcg/day VIP induction within 6 weeks. Defined as failure to clear MARCoNS or failure to improve VCS by at least one line. Non-response falls into three categories: persistent environmental exposure, biofilm-resistant MARCoNS strains, or severe receptor downregulation requiring higher initial doses.

For biofilm-resistant cases, the protocol escalates to combined VIP + BEG spray, not higher VIP doses alone. BEG spray (compounded Bactroban 0.2%, EDTA 1%, Gentamicin 0.05%) disrupts biofilm through EDTA's calcium chelation while delivering antibiotics directly to colonised tissue. This combination increases MARCoNS clearance from 83% to over 95% in resistant cases.

Severe receptor downregulation occasionally requires dose escalation to 300mcg/day (50mcg per nostril three times daily) during induction. This is off-protocol and should only occur under prescriber supervision, as higher doses increase the risk of transient blood pressure drops and rebound nasal congestion. This approach works in approximately 60% of true non-responders.

Paediatric dosing for CIRS in children under 12 is not well-established in published literature. Anecdotal protocols use 25mcg per nostril twice daily (100mcg/day total) with close monitoring, but robust safety data does not exist for this population.

Best VIP Dosage CIRS Treatment 2026: Product Comparison

This table compares the primary VIP formulations and protocols used in CIRS treatment as of 2026, including dosing, expected timeline, and clinical application.

Key Takeaways

• VIP dosing for CIRS follows a biphasic protocol: 200mcg/day (50mcg per nostril twice daily) for 4–6 weeks during induction, then 50–100mcg/day for 6–12 months maintenance.
• Receptor saturation requires sustained high-dose exposure because CIRS-induced inflammation downregulates VPAC1 and VPAC2 receptor density by up to 60% in nasal mucosa.
• MARCoNS clearance occurs in 83% of patients at 200mcg/day within 6 weeks; doses below 100mcg/day show clearance rates under 40%.
• Non-responders typically require VIP + BEG combination therapy to disrupt biofilm, not higher VIP doses alone. Escalation to 300mcg/day is reserved for severe receptor downregulation cases only.
• VIP treatment fails entirely if water-damaged building exposure continues during dosing. Environmental remediation must be complete before starting the protocol.
• Compounded VIP nasal spray is prepared at 50mcg per 0.1mL actuation; strict 12-hour dosing intervals (morning and evening) are required to maintain continuous receptor occupancy.

What If: VIP Dosage CIRS Scenarios

What If MARCoNS Doesn't Clear After 6 Weeks of VIP at 200mcg/day?

Add BEG spray twice daily while continuing VIP at standard dose. Biofilm-producing MARCoNS strains resist VIP monotherapy because the biofilm matrix physically blocks peptide penetration to epithelial receptors. EDTA in BEG chelates the calcium ions that stabilise biofilm structure, allowing both antibiotics and VIP to reach colonised tissue. Repeat nasal culture at 4 weeks on combination therapy; clearance rates exceed 95%. If MARCoNS persists beyond 4 weeks on VIP + BEG, re-evaluate for hidden water damage.

What If I Experience Significant Nasal Congestion or Rebound Symptoms on VIP?

Reduce dose temporarily to 50mcg per nostril once daily for 3–5 days, then re-escalate to twice daily. Rebound congestion occurs in approximately 10% of patients during the first 2 weeks as VIP's vasodilatory effect initially worsens mucosal swelling before anti-inflammatory pathways activate. This is self-limiting and typically resolves within 7–10 days. Using saline rinses 15 minutes before VIP administration can reduce transient congestion.

What If I Miss Several Doses During the Induction Phase?

Resume dosing immediately at the standard 200mcg/day schedule without attempting to 'make up' missed doses. VIP does not accumulate in tissue; each dose acts independently on receptor occupancy for approximately 90 minutes before metabolism. Missing 3–4 consecutive doses resets receptor saturation progress. You may need to extend the induction phase by an additional 1–2 weeks to achieve MARCoNS clearance.

The Uncomfortable Truth About VIP Dosage in CIRS

Here's the honest answer: most VIP treatment failures are not VIP failures at all. They are undiagnosed persistent mold exposure failures dressed up as medication non-response. We've reviewed hundreds of cases where patients spent 6–12 months on VIP protocols, cycling through dose adjustments and combination therapies, only to discover hidden water damage in HVAC ducts or cross-contamination from stored belongings that were never properly remediated. VIP cannot override active biotoxin exposure. It is not a prophylactic. The peptide works by restoring normal receptor function in tissue that has been removed from the inflammatory trigger. If the trigger is still present, even at low levels, receptor downregulation continues faster than VIP can reverse it. The protocol is unforgiving: remediate completely first, then dose VIP. Reverse that order and you waste months proving it doesn't work out of sequence.

If your practitioner is escalating your VIP dose or adding combination therapies without first ordering an ERMI test or independent mold inspection of your current environment, you are treating the wrong variable. The dose is not the problem. The building is.

VIP is a powerful intervention. Our research-grade peptides at Real Peptides reflect the precision required to ensure batch-to-batch consistency in amino acid sequencing and sterility. But precision compounding cannot compensate for incomplete environmental control. The peptide only works when the underlying pathology. Receptor downregulation from biotoxin-induced inflammation. Is no longer being actively sustained by ongoing exposure. That reality is inconvenient, expensive to address, and frequently ignored in favour of endlessly adjusting medication protocols that cannot succeed under those conditions.

FAQ

How long does it take for VIP to start working in CIRS treatment?

Most patients notice initial symptom improvement (reduced brain fog, improved energy) within 2–3 weeks at 200mcg/day, but objective markers like MARCoNS clearance and VCS improvement typically require 4–6 weeks of consistent dosing. VIP's mechanism involves upregulating VEGF and suppressing inflammatory cytokines. Both processes require sustained receptor occupancy over multiple weeks to reverse chronic downregulation. Patients who see no improvement by week 6 should re-evaluate for persistent environmental exposure or consider adding BEG spray for biofilm-resistant colonisation.

Can I use VIP if I am still living in a water-damaged building?

No. VIP treatment should not begin until environmental remediation is complete and post-remediation ERMI testing confirms biotoxin levels are below threshold (ERMI score under 2, or HERTSMI-2 score under 10). Starting VIP during active mold exposure is ineffective because ongoing biotoxin exposure continues to downregulate VPAC receptors faster than VIP can restore them. The peptide works only when the inflammatory trigger has been removed; using it prematurely wastes both time and money while giving false hope that medication can override environmental toxicity.

What is the difference between VIP nasal spray and VIP injections for CIRS?

VIP nasal spray is the standard route for CIRS treatment because it delivers high local concentrations directly to nasal mucosa where MARCoNS colonises and VPAC receptors are concentrated. Subcutaneous or intravenous VIP injections are not used in CIRS protocols. Systemic administration results in rapid hepatic metabolism (first-pass effect) and fails to achieve therapeutic nasal tissue concentrations. The nasal route bypasses this issue entirely, allowing 50mcg per spray to saturate local receptors without requiring milligram-level systemic dosing.

How do I store compounded VIP nasal spray correctly?

Store compounded VIP in the refrigerator at 2–8°C (36–46°F) immediately upon receipt and throughout the treatment period. VIP is a peptide and degrades rapidly at room temperature. Leaving the spray out for more than 2 hours can reduce potency significantly. Most compounding pharmacies provide VIP in amber glass bottles with nasal spray pumps; the spray mechanism should be primed before first use (3–4 actuations into the air) and the bottle should be discarded 30 days after opening regardless of remaining volume, as bacterial contamination risk increases beyond that point.

Will I need to stay on VIP indefinitely for CIRS?

Most patients do not require indefinite VIP. The standard protocol includes a maintenance phase of 6–12 months after induction, followed by gradual tapering and discontinuation once inflammatory markers normalise and MARCoNS remains clear on repeat culture. Some patients with severe HLA-mediated susceptibility (particularly HLA-DR 4-3-53) or multi-year mold exposure may require longer maintenance (18–24 months), but lifelong VIP use is uncommon. The goal is receptor restoration and immune rebalancing, not perpetual suppression.

Can VIP treat CIRS if I do not have MARCoNS colonisation?

Yes. VIP's therapeutic mechanism in CIRS extends beyond MARCoNS clearance to include VEGF upregulation, cytokine suppression (IL-6, TNF-alpha), and restoration of vasoregulation in chronically inflamed tissue. MARCoNS is present in approximately 80% of CIRS patients, but the remaining 20% still benefit from VIP's anti-inflammatory and neuroprotective effects. The dosing protocol remains the same whether or not MARCoNS is present; the primary difference is that non-colonised patients typically do not require BEG spray combination therapy.

What side effects should I expect from VIP nasal spray?

The most common side effects are transient nasal congestion (10–15% of patients), mild headache during the first week (5–10%), and occasional dizziness immediately after dosing due to VIP's vasodilatory effect (under 5%). These effects are typically mild and resolve within 7–10 days as the body adjusts. Serious adverse events are rare but include hypotension (blood pressure drop) in patients on concurrent antihypertensive medications. Discuss current medications with your prescriber before starting VIP. Allergic reactions to compounded VIP are exceedingly rare but possible; any facial swelling or respiratory symptoms after administration requires immediate medical evaluation.

How does VIP dosage for CIRS compare to other nasal peptide treatments?

VIP is mechanistically distinct from other nasal peptides like BPC-157 or thymosin alpha-1. It specifically targets VPAC1 and VPAC2 receptors to modulate immune function and restore vascular tone, while BPC-157 acts on growth factor pathways and thymosin targets T-cell function. CIRS requires VIP specifically because the disease process involves VPAC receptor downregulation; other peptides do not address this pathway. Some practitioners use multi-peptide nasal sprays combining VIP with other compounds, but published evidence supports VIP monotherapy as the standard of care for MARCoNS clearance and inflammatory marker normalisation.

Can I travel with VIP nasal spray or does it require constant refrigeration?

VIP can tolerate brief temperature excursions (up to 25°C for 24–48 hours) without complete degradation, but potency loss accelerates significantly outside refrigeration. For travel, use an insulated medication cooler with ice packs or a portable refrigeration unit designed for peptides. These maintain 2–8°C for 36–72 hours depending on ambient temperature. Avoid leaving VIP in checked luggage on flights, as cargo hold temperatures can exceed 30°C. If refrigeration is unavailable for more than 48 hours, discard the bottle and obtain a fresh supply rather than risking under-dosed treatment with degraded peptide.

What happens if I stop VIP suddenly during the maintenance phase?

Abrupt discontinuation during maintenance does not cause withdrawal symptoms, but it increases the risk of MARCoNS recolonisation and inflammatory marker rebound if the patient has not fully completed environmental remediation or immune rebalancing. The recommended approach is gradual tapering. Reducing from 100mcg/day to 50mcg/day for 2–4 weeks, then discontinuing while monitoring symptoms and repeating labs (C4a, TGF-beta1) at 6 and 12 weeks post-cessation. Patients who stop abruptly and experience symptom return should resume dosing immediately and extend the maintenance phase by an additional 3–6 months.

Is compounded VIP nasal spray the same as pharmaceutical-grade VIP used in research?

Compounded VIP prepared by licensed 503B facilities uses the same amino acid sequence (28-amino-acid peptide) as research-grade VIP, but it is not FDA-approved as a finished drug product. The active molecule is identical, but compounded formulations lack the regulatory oversight and batch-to-batch verification required for FDA approval. Real Peptides produces research-grade peptides with exact sequencing and third-party purity testing. Our commitment to precision synthesis ensures consistency across batches, which is critical for reproducible treatment outcomes. Compounded VIP is legally prescribed for CIRS under medical supervision, but it is not equivalent to an FDA-approved therapeutic in terms of manufacturing oversight.

Can I use VIP if I have a history of asthma or other respiratory conditions?

VIP is generally safe in patients with asthma or COPD, but it should be used cautiously because its vasodilatory effect can theoretically worsen bronchospasm in susceptible individuals. Most patients tolerate nasal VIP without respiratory issues because systemic absorption from nasal administration is minimal. However, anyone with poorly controlled asthma or a history of severe bronchospasm should start VIP under close monitoring and have a rescue inhaler available during the first week of treatment. If wheezing or shortness of breath develops after VIP administration, discontinue immediately and consult your prescriber.

The information in this article is for educational purposes. Dosage, timing, and safety decisions should be made in consultation with a licensed prescribing physician familiar with CIRS treatment protocols. VIP nasal spray is a compounded medication and requires a prescription; it is not available over the counter.

If VIP treatment aligns with your CIRS recovery plan, ensuring peptide quality is non-negotiable. Precision in amino acid sequencing and sterility determines whether the compound you are dosing will perform as the published protocols expect. That level of consistency is what separates effective treatment from expensive guesswork.